An initiation visit took place: patients with Crohn's disease will continue to participate in a new multicenter open extended phase 3 study to assess the long-term efficacy and safety of Mirikizumab in patients with Crohn's disease.
Our Study Site was invited to participate in clinical trials conducted by the Japanese pharmaceutical company Astellas Pharma
Recruitment of patients to the Phase III study 14-431 to evaluate the efficacy and safety of ABT-494 in patients with Crohn's disease has been properly completed.
Permission from the Ministry of Health of the Russian Federation has been obtained to conduct a clinical trial of GALACTIC-1 phase IIb for patients with Idiopathic Pulmonary Fibrosis.
